Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic …
2022年12月13日 · In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
Sustained benefit of zanubrutinib vs ibrutinib in patients with …
2024年12月26日 · The ALPINE trial established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic …
An ALPINE guide to covalent BTKis in CLL
2024年12月26日 · The superior efficacy in ALPINE of zanubrutinib vs ibrutinib occurred across all parameters of PFS, at the index point of 36 months, and for the overall population was 65.4% …
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic ...
2022年11月17日 · ALPINE (ClinicalTrials.gov identifier: NCT03734016) is a global, randomized, open-label phase III study of zanubrutinib versus ibrutinib in patients with relapsed/refractory …
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic …
2023年1月26日 · In prespecified interim analyses, zanubrutinib was superior to ibrutinib with respect to overall response (the primary end point). Data from the final analysis of progression …
Sustained benefit of zanubrutinib vs ibrutinib in patients with …
2024年12月26日 · Zanubrutinib is a uniquely designed BTKi specifically developed for greater BTK specificity and increased potency compared with ibrutinib and acalabrutinib. 3 With …
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic ...
2023年2月10日 · Zanubrutinib had a significantly higher ORR, lower atrial fibrillation rate, and improved progression-free survival and overall cardiac safety profile versus ibrutinib. These …
ALPINE: After 39 Months, Zanubrutinib Keeps Its PFS Edge Over Ibrutinib …
2023年12月9日 · At 39 months, patients taking zanubrutinib after 1 prior treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia retained a 32% edge in …
Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients
2024年9月24日 · ALPINE (NCT03734016) established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small …
Comparison of Zanubrutinib and Ibrutinib As Treatments for …
2024年11月5日 · We report the first real-world, multicenter retrospective study comparing ibrutinib and zanubrutinib as treatment for WM implementing PSM to minimize bias. Mortality rate of …
- 某些结果已被删除